



The NEW ENGLAND JOURNAL of MEDICINE

INTEGRITY SAFEGUARDS

The *New England Journal of Medicine* is committed to publishing the highest quality research and reliable, authoritative review articles that are free from commercial influence. The mainstays of the *Journal's* credibility are editorial independence, content uninterrupted by commercial advertising, and academic rigor in reviewing research.

Since the 1980s, editors of the *Journal* have set policies to ensure that authors disclose their financial associations and that those financial associations do not influence published content. Its rules are methodical and stringent. The *Journal* is sensitive to even the appearance of impropriety.

The *Journal* announced its first conflict-of-interest policy in 1984. Since then, the policy has undergone limited, considered revisions owing to the changing environment of medical research.

For all research articles we publish, the *Journal* lists study sponsorship and relevant financial information as disclosed by the authors. We ask authors for details concerning their financial relationships with biomedical companies, including consulting fees, service on advisory boards, ownership of equity (or options), patent royalties, honorariums for lectures, fees for expert testimony, and research grants. Information of relevance to the reported research is provided in a disclosure at the end of the report. Additional information about the contributions of authors may also appear in the Methods section of research articles.

A separate policy applies to Review Articles and editorials, which comment on published articles but do not present new data. The *Journal* asks that authors of such articles not have any significant financial interest in a public or private company (or its competitor) that makes a product discussed in the article. Relationships that occur within two years before the publication date of an article are considered pertinent. The word “significant” acknowledges that not all financial associations are the same. The *Journal's* intent is to focus on financial relationships that it believes could produce bias, or the perception of bias, in an article. The *Journal* also requires that authors of Review Articles and editorials, through their institutions, not receive major research support or a major proportion of their funding from relevant companies.

No *Journal* editor responsible for weighing the available facts about a prospective author or article has any financial relationship with any biomedical company.